3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Endometrial Neoplasms
2
Breast Neoplasms
2
Smoking
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Peripheral Nervous System Diseases
1
Overweight
1
Obesity
1
Motor Activity
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Localized Prostate Cancer
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Infertility
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Genetic Diseases, Inborn
1
Cognitive Dysfunction
1
Interventions
Cyclophosphamide
30
Rituximab
27
Biopsy
23
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
fludarabine
14
Prednisone
13
Vincristine
11
obinutuzumab
10
Lenalidomide
10
Etoposide
10
Doxorubicin
10
Bendamustine Hydrochloride
9
venetoclax
7
pembrolizumab
7
fludarabine phosphate
6
X-Rays
6
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Dexamethasone
6
Bortezomib
6
trametinib
5
ibrutinib
5
glofitamab
5
acalabrutinib
5
Mycophenolic Acid
5
Gemcitabine
5
Crizotinib
5
Busulfan
5
copanlisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
Tablets
×
90 days
×
Clear all
NCT06643221
2026-06-05
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
200 enrolled